Review

seldi‐tof proteinchip reader (Ciphergen inc)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Ciphergen inc seldi‐tof proteinchip reader
Comparison of human tear proteome studies concerning patients affected by ocular diseases

Seldi‐Tof Proteinchip Reader, supplied by Ciphergen inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/seldi‐tof proteinchip reader/product/Ciphergen inc
Average 90 stars, based on 1 article reviews

seldi‐tof proteinchip reader - by Bioz Stars, 2026-06

90/100 stars

Images

1) Product Images from "Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery"

Article Title: Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

Journal: Mass Spectrometry Reviews

doi: 10.1002/mas.21691

Figure Legend Snippet: Comparison of human tear proteome studies concerning patients affected by ocular diseases

Techniques Used: Software, Biomarker Assay

Figure Legend Snippet: Comparison of human tear proteome studies concerning patients affected by systemic diseases

Techniques Used: Software

Similar Products

seldi‐tof proteinchip reader (Ciphergen inc)

Ciphergen inc seldi‐tof proteinchip reader

seldi‐tof proteinchip reader - by Bioz Stars, 2026-06

90/100 stars

Buy from Supplier

seldi‐tof proteinchip reader pbs ii (Ciphergen inc)

Ciphergen inc seldi‐tof proteinchip reader pbs ii

Seldi‐Tof Proteinchip Reader Pbs Ii, supplied by Ciphergen inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/seldi‐tof proteinchip reader pbs ii/product/Ciphergen inc
Average 90 stars, based on 1 article reviews

seldi‐tof proteinchip reader pbs ii - by Bioz Stars, 2026-06

90/100 stars

Buy from Supplier

proteinchip® seldi-tof reader pcs4000 ms-tof enterprise (Bio-Rad)

Bio-Rad proteinchip® seldi-tof reader pcs4000 ms-tof enterprise
$Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. <t>ProteinChip®,</t> matrix and laser intensity conditions are detailed in Table 2.$
Proteinchip® Seldi Tof Reader Pcs4000 Ms Tof Enterprise, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteinchip® seldi-tof reader pcs4000 ms-tof enterprise/product/Bio-Rad
Average 90 stars, based on 1 article reviews

proteinchip® seldi-tof reader pcs4000 ms-tof enterprise - by Bioz Stars, 2026-06

90/100 stars

Buy from Supplier

proteinchip® seldi reader pcs4000 ms-tof enterprise (Bio-Rad)

Bio-Rad proteinchip® seldi reader pcs4000 ms-tof enterprise
$Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. <t>ProteinChip®,</t> matrix and laser intensity conditions are detailed in Table 2.$
Proteinchip® Seldi Reader Pcs4000 Ms Tof Enterprise, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteinchip® seldi reader pcs4000 ms-tof enterprise/product/Bio-Rad
Average 90 stars, based on 1 article reviews

proteinchip® seldi reader pcs4000 ms-tof enterprise - by Bioz Stars, 2026-06

90/100 stars

Buy from Supplier

proteinchip r© reader series 4000 seldi-tof mass spectrometer (Bio-Rad)

Bio-Rad proteinchip r© reader series 4000 seldi-tof mass spectrometer
$Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. <t>ProteinChip®,</t> matrix and laser intensity conditions are detailed in Table 2.$
Proteinchip R© Reader Series 4000 Seldi Tof Mass Spectrometer, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/proteinchip r© reader series 4000 seldi-tof mass spectrometer/product/Bio-Rad
Average 90 stars, based on 1 article reviews

proteinchip r© reader series 4000 seldi-tof mass spectrometer - by Bioz Stars, 2026-06

90/100 stars

Buy from Supplier

seldi-tof ms proteinchip reader, series pcs4000 (Ciphergen inc)

Ciphergen inc seldi-tof ms proteinchip reader, series pcs4000
$Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. <t>ProteinChip®,</t> matrix and laser intensity conditions are detailed in Table 2.$
Seldi Tof Ms Proteinchip Reader, Series Pcs4000, supplied by Ciphergen inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/seldi-tof ms proteinchip reader, series pcs4000/product/Ciphergen inc
Average 90 stars, based on 1 article reviews

seldi-tof ms proteinchip reader, series pcs4000 - by Bioz Stars, 2026-06

90/100 stars

Buy from Supplier

seldi-tof ms proteinchip reader (Ciphergen inc)

Ciphergen inc seldi-tof ms proteinchip reader
$Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. <t>ProteinChip®,</t> matrix and laser intensity conditions are detailed in Table 2.$
Seldi Tof Ms Proteinchip Reader, supplied by Ciphergen inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/seldi-tof ms proteinchip reader/product/Ciphergen inc
Average 90 stars, based on 1 article reviews

seldi-tof ms proteinchip reader - by Bioz Stars, 2026-06

90/100 stars

Buy from Supplier

pcs4000 seldi-tof ms proteinchip reader (Ciphergen inc)

Ciphergen inc pcs4000 seldi-tof ms proteinchip reader
$Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. <t>ProteinChip®,</t> matrix and laser intensity conditions are detailed in Table 2.$
Pcs4000 Seldi Tof Ms Proteinchip Reader, supplied by Ciphergen inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcs4000 seldi-tof ms proteinchip reader/product/Ciphergen inc
Average 90 stars, based on 1 article reviews

pcs4000 seldi-tof ms proteinchip reader - by Bioz Stars, 2026-06

90/100 stars

Buy from Supplier

seldi-tof-ms proteinchip reader (Ciphergen inc)

Ciphergen inc seldi-tof-ms proteinchip reader
$Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. <t>ProteinChip®,</t> matrix and laser intensity conditions are detailed in Table 2.$
Seldi Tof Ms Proteinchip Reader, supplied by Ciphergen inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/seldi-tof-ms proteinchip reader/product/Ciphergen inc
Average 90 stars, based on 1 article reviews

seldi-tof-ms proteinchip reader - by Bioz Stars, 2026-06

90/100 stars

Buy from Supplier

Image Search Results

Journal: Mass Spectrometry Reviews

Article Title: Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

doi: 10.1002/mas.21691

Figure Lengend Snippet: Comparison of human tear proteome studies concerning patients affected by ocular diseases

Article Snippet: Grus et al. ( ) , DED , Single subject, 1 take , STS , 20 μl , ProteinChip Array , None , None , None , None , SELDI‐TOF Ciphergen ProteinChip Reader PBS II (Ciphergen Biosystems) , Full scan , Ciphergen Express Data Manager , N/D.

Techniques: Software, Biomarker Assay

Journal: Mass Spectrometry Reviews

Article Title: Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

doi: 10.1002/mas.21691

Figure Lengend Snippet: Comparison of human tear proteome studies concerning patients affected by systemic diseases

Techniques: Software

Journal: Mass Spectrometry Reviews

Article Title: Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

doi: 10.1002/mas.21691

Figure Lengend Snippet: Comparison of human tear proteome studies concerning patients affected by ocular diseases

Article Snippet: Tomosugi et al. ( ) , DED, SS , Single subject, 1 take , STS , 24 μl , ProteinChip Array , None , None , None , None , SELDI‐TOF Ciphergen ProteinChip Reader PBS II (Ciphergen Biosystems) , Full scan , Biomarker Wizard , 56.

Techniques: Software, Biomarker Assay

Journal: Mass Spectrometry Reviews

Article Title: Mass spectrometry‐based tear proteomics for noninvasive biomarker discovery

doi: 10.1002/mas.21691

Figure Lengend Snippet: Comparison of human tear proteome studies concerning patients affected by systemic diseases

Techniques: Software

$Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. ProteinChip®, matrix and laser intensity conditions are detailed in Table 2.$

Journal: American Journal of Translational Research

Article Title: Targeting TNFα in severe psoriasis-mass spectrometry reveals a time-dependent specific inhibition of Factor H in responding patients

doi:

Figure Lengend Snippet: Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. ProteinChip®, matrix and laser intensity conditions are detailed in Table 2.

Article Snippet: ProteinChip®-captured proteins were detected using a ProteinChip® SELDI-TOF reader PCS4000 MS-TOF Enterprise (Bio-Rad).

Techniques: MANN-WHITNEY